Exploring the clinical pharmacokinetics and pharmacodynamics of SGLT2 inhibitor, empagliflozin: a systematic review

Key Points

• The review aims to consolidate pharmacokinetic and pharmacodynamic data for empagliflozin to guide clinical use in specific populations.
• Systematic review of available studies on empagliflozin's pharmacokinetics (PK) and pharmacodynamics (PD).
• Analysis focused on patients with renal and hepatic impairment and type 2 diabetes.
• Evaluation aimed at determining optimal dosing and minimizing adverse drug interactions.
• Empagliflozin PK parameters showed a 1.1-fold increase when given alone, but reduced in combination with linagliptin.
• Findings assist in clinical decision-making regarding dose adjustments in special populations.
• Highlights the importance of monitoring for adverse reactions and drug interactions in patients.

Abstract